Vesna Višekruna Vučina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vesna Višekruna Vučina has a total of 330 co-authors. Here are the top co-authors by number of shared publications:
- Esther Kissling
EpiConcept, Paris, France
10 shared publications Francisco Pozo
Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
10 shared publicationsMihaela Lazar
12National Influenza Centre, Cantacuzino National Military-Medical Institute for Research and Development, Romania
9 shared publicationsSilke Buda
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
9 shared publicationsAdam Meijer
National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
8 shared publicationsAna Paula Rodrigues
Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
7 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (6) , 103
Rubella Antibody Prevalence Among Women of Reproductive Age in Croatia: Implications for the Prevention of Congenital Rubella Syndrome
Background/Objectives: Rubella immunity in childbearing-aged women is crucial due to the risk of congenital rubella syndrome (CRS). This study analyzed temporal trends in rubella virus (RUBV) seroprevalence among women of reproductive age in Croatia. Methods: The study included 1490 childbearing-aged and pregnant women aged 16–45 years tested between January 2015 and December 2024. RUBV IgM and IgG antibodies were detected using a commercial ELISA, with IgM-positive samples further assessed for IgG avidity. Results: RUBV IgG antibodies were detected in 1407/1490 (94.4%) of participants, with significant differences between years ranging from 87.4% (2019) to 96.4% (2023). High seropositivity was observed across all age groups, with no significant differences (93.1–95.1%). The area of residence was not associated with seroprevalence (continental Croatia: 94.8%, coastal Croatia: 93.8%). Similarly, no significant differences in seropositivity were observed according to settlement type (urban regions: 94.1%, suburban/rural regions: 95.1%). The year of sampling was the only predictor that showed significance in the multivariate regression model. A statistically significant effect of calendar year was demonstrated, indicating that the odds of IgG seropositivity increased by approximately 8% per year. Conclusions: This study demonstrated consistently high RUBV seroprevalence among Croatian women of reproductive age across all age groups during the past decade. Maintaining this high level of immunity is crucial for the prevention of CRS.
- 3 November 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (6) , 103
Open AccessRubella Antibody Prevalence Among Women of Reproductive Age in Croatia: Implications for the Prevention of Congenital Rubella Syndrome
Background/Objectives: Rubella immunity in childbearing-aged women is crucial due to the risk of congenital rubella syndrome (CRS). This study analyzed temporal trends in rubella virus (RUBV) seroprevalence among women of reproductive age in Croatia. Methods: The study included 1490 childbearing-aged and pregnant women aged 16–45 years tested between January 2015 and December 2024. RUBV IgM and IgG antibodies were detected using a commercial ELISA, with IgM-positive samples further assessed for IgG avidity. Results: RUBV IgG antibodies were detected in 1407/1490 (94.4%) of participants, with significant differences between years ranging from 87.4% (2019) to 96.4% (2023). High seropositivity was observed across all age groups, with no significant differences (93.1–95.1%). The area of residence was not associated with seroprevalence (continental Croatia: 94.8%, coastal Croatia: 93.8%). Similarly, no significant differences in seropositivity were observed according to settlement type (urban regions: 94.1%, suburban/rural regions: 95.1%). The year of sampling was the only predictor that showed significance in the multivariate regression model. A statistically significant effect of calendar year was demonstrated, indicating that the odds of IgG seropositivity increased by approximately 8% per year. Conclusions: This study demonstrated consistently high RUBV seroprevalence among Croatian women of reproductive age across all age groups during the past decade. Maintaining this high level of immunity is crucial for the prevention of CRS.
- Open Access
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16–2024/25
1. Seasonal influenza remains a major cause of morbidity and mortality worldwide, particularly among older adults [1]. Individuals aged 65 years account for a substantial proportion of influenza-a...
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Open AccessAssociation between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16–2024/25
1. Seasonal influenza remains a major cause of morbidity and mortality worldwide, particularly among older adults [1]. Individuals aged 65 years account for a substantial proportion of influenza-a...
- Open Access
Assessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015–2025
Background/Objectives: Measles is a highly contagious infectious disease. Maintaining a high level of measles immunity in the population is essential due to the extremely high transmissibility of the measles virus (MV). We analyzed the MV seroprevalence in the Croatian population. Methods: A total of 1998 individuals tested consecutively for MV antibodies from 2015 to 2025 inclusive were included. MV IgG antibodies were detected using a commercial ELISA. Results: The overall seroprevalence rate was 75.1%, with significant yearly differences, ranging from 50.0 to 86.5%, and a declining trend since 2023. No differences were observed between sexes (males 71.6%, females 71.9%). The seroprevalence increased with age, from 60.9% in the 1–10 age group to 91.1% in the 61+ age group. Significant geographic differences were found, with higher seropositivity rates in coastal regions compared to continental regions (81.3 and 71.0%, respectively). Settlement type (urban, suburban/rural) was not associated with the MV seroprevalence. The results of the multivariable logistic regression analysis showed that year, age, and region were significantly associated with IgG seropositivity. Each additional calendar year was associated with lower odds of IgG positivity (OR = 0.82), while each additional year of age was associated with higher odds (OR = 1.04). Region was also a significant predictor (OR = 1.65), while settlement was not significantly associated with seropositivity after adjustment for other variables. Conclusions: Croatia has historically maintained high measles coverage, but lower uptake in some regions and age groups may be creating immunity gaps. The lower post-2022 seropositivity underscores significant immunity gaps, particularly among highly susceptible groups that were exposed to outbreaks and tested during that period.
Open AccessAssessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015–2025
Background/Objectives: Measles is a highly contagious infectious disease. Maintaining a high level of measles immunity in the population is essential due to the extremely high transmissibility of the measles virus (MV). We analyzed the MV seroprevalence in the Croatian population. Methods: A total of 1998 individuals tested consecutively for MV antibodies from 2015 to 2025 inclusive were included. MV IgG antibodies were detected using a commercial ELISA. Results: The overall seroprevalence rate was 75.1%, with significant yearly differences, ranging from 50.0 to 86.5%, and a declining trend since 2023. No differences were observed between sexes (males 71.6%, females 71.9%). The seroprevalence increased with age, from 60.9% in the 1–10 age group to 91.1% in the 61+ age group. Significant geographic differences were found, with higher seropositivity rates in coastal regions compared to continental regions (81.3 and 71.0%, respectively). Settlement type (urban, suburban/rural) was not associated with the MV seroprevalence. The results of the multivariable logistic regression analysis showed that year, age, and region were significantly associated with IgG seropositivity. Each additional calendar year was associated with lower odds of IgG positivity (OR = 0.82), while each additional year of age was associated with higher odds (OR = 1.04). Region was also a significant predictor (OR = 1.65), while settlement was not significantly associated with seropositivity after adjustment for other variables. Conclusions: Croatia has historically maintained high measles coverage, but lower uptake in some regions and age groups may be creating immunity gaps. The lower post-2022 seropositivity underscores significant immunity gaps, particularly among highly susceptible groups that were exposed to outbreaks and tested during that period.
- 6 April 2026
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (5)
Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022–2024
OBJECTIVES: To estimate influenza vaccine effectiveness (VE) in the pediatric population (<18 years) attending primary care in the European Union and European Economic Area in 2022/2023 and 2023/2024. METHODS: General practitioners swabbed and interviewed patients with acute respiratory tract infection. We conducted a test-negative case-control study and used logistic regression to estimate VE against any influenza and specific (sub)types, overall and by age group, and within the vaccine recommendation target group. RESULTS: Among 10 368 children in 2022/23, 3286 (32%) tested polymerase chain reaction-positive for influenza virus; among 9270 children in 2023/24, 1567 (17%) tested positive. Influenza A(H3N2) and B predominated in 2022/23, and influenza A(H1N1)pdm09 in 2023/24. Among the test-negative controls, 17% were part of the vaccine recommendation target group in 2022/23 and 38% in 2023/24. In 2022/23, overall VE against any influenza was 68% (95% CI: 59–76); 57% (95% CI: 26–76) against influenza A(H1N1)pdm09; 54% (95% CI: 33–69) against influenza A(H3N2); 83% (95% CI: 74–90) against influenza B. In 2023/24, overall VE against any influenza was 71% (95% CI: 62–78); 75% (95% CI: 64–83) against influenza A(H1N1)pdm09; 40% (95% CI: 4–64) against influenza A(H3N2); and 92% (95% CI: 63–100) against influenza B. All VE estimates varied by age and vaccine recommendation target group. CONCLUSIONS: In 2022/23 and 2023/24, more than two-thirds of vaccinated children were protected against primary care-attended influenza infection in Europe. Monitoring VE in children can help inform influenza immunization programs.
- 6 April 2026
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (5)
Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022–2024
OBJECTIVES: To estimate influenza vaccine effectiveness (VE) in the pediatric population (<18 years) attending primary care in the European Union and European Economic Area in 2022/2023 and 2023/2024. METHODS: General practitioners swabbed and interviewed patients with acute respiratory tract infection. We conducted a test-negative case-control study and used logistic regression to estimate VE against any influenza and specific (sub)types, overall and by age group, and within the vaccine recommendation target group. RESULTS: Among 10 368 children in 2022/23, 3286 (32%) tested polymerase chain reaction-positive for influenza virus; among 9270 children in 2023/24, 1567 (17%) tested positive. Influenza A(H3N2) and B predominated in 2022/23, and influenza A(H1N1)pdm09 in 2023/24. Among the test-negative controls, 17% were part of the vaccine recommendation target group in 2022/23 and 38% in 2023/24. In 2022/23, overall VE against any influenza was 68% (95% CI: 59–76); 57% (95% CI: 26–76) against influenza A(H1N1)pdm09; 54% (95% CI: 33–69) against influenza A(H3N2); 83% (95% CI: 74–90) against influenza B. In 2023/24, overall VE against any influenza was 71% (95% CI: 62–78); 75% (95% CI: 64–83) against influenza A(H1N1)pdm09; 40% (95% CI: 4–64) against influenza A(H3N2); and 92% (95% CI: 63–100) against influenza B. All VE estimates varied by age and vaccine recommendation target group. CONCLUSIONS: In 2022/23 and 2023/24, more than two-thirds of vaccinated children were protected against primary care-attended influenza infection in Europe. Monitoring VE in children can help inform influenza immunization programs.
- Open Access
- 12 June 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (23) , 2500011
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24
Introduction: Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years. Aim: The VEBIS primary care network estimated influenza VE in Europe using a multicentre test‐negative study. Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression. Results: We included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44–59). By year of age, VE was 27% (95% CI: −2 to 47) at 44 years with peaks at 72% (95% CI: 52–84) and 54% (95% CI: 41–64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24–54) and −11% (95% CI: −69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20–48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1–62). All-age VE against B/Victoria was 83% (95% CI: 65–94), ranging between 70 and 92% by age group. Discussion: The 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.
- 12 June 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (23) , 2500011
Open AccessInfluenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24
Introduction: Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years. Aim: The VEBIS primary care network estimated influenza VE in Europe using a multicentre test‐negative study. Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression. Results: We included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44–59). By year of age, VE was 27% (95% CI: −2 to 47) at 44 years with peaks at 72% (95% CI: 52–84) and 54% (95% CI: 41–64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24–54) and −11% (95% CI: −69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20–48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1–62). All-age VE against B/Victoria was 83% (95% CI: 65–94), ranging between 70 and 92% by age group. Discussion: The 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.
- Open Access
- 22 February 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (8) , 2400089
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
- 22 February 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (8) , 2400089
Open AccessInterim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
- Open Access
- 10 January 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (1) , e13243
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
Background: Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test‐negative study.Materials and Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression.Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25–45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25–49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35–56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46–65) and 79% (95% CI: 64–88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70–81); overall, 84%, 72% and 71% were among 0–14‐year‐olds, 15–64‐year‐olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73–85) and 90% (95% CI: 85–94) without this mutationConclusion: The 2022–2023 end‐of‐season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).
- 10 January 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (1) , e13243
Open AccessInfluenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
Background: Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test‐negative study.Materials and Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression.Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25–45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25–49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35–56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46–65) and 79% (95% CI: 64–88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70–81); overall, 84%, 72% and 71% were among 0–14‐year‐olds, 15–64‐year‐olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73–85) and 90% (95% CI: 85–94) without this mutationConclusion: The 2022–2023 end‐of‐season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).
- Open Access
- 10 October 2023
- Published by Wiley
Influenza vaccine effectiveness in Europe: Results from the 2022–23 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression. We included 38,058 patients, of which 3,786 were influenza A(H3N2), 1,548 influenza A(H1N1)pdm09 and 3,275 influenza B cases. Against influenza A(H3N2), VE was 36% (95%CI: 25–45) among all ages, ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25–49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95%CI: 35–56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46–65) and 79% (95% CI: 64–88) against clade 5a.2a.1. VE against influenza B was 76% (95%CI: 70–81), overall; 84%, 72% and 71% among 0–14-year-olds 15–64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197-mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73–85) and 90% (95% CI: 85–94) without this mutation. The 2022–23 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).
- 10 October 2023
- Published by Wiley
Open AccessInfluenza vaccine effectiveness in Europe: Results from the 2022–23 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression. We included 38,058 patients, of which 3,786 were influenza A(H3N2), 1,548 influenza A(H1N1)pdm09 and 3,275 influenza B cases. Against influenza A(H3N2), VE was 36% (95%CI: 25–45) among all ages, ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25–49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95%CI: 35–56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46–65) and 79% (95% CI: 64–88) against clade 5a.2a.1. VE against influenza B was 76% (95%CI: 70–81), overall; 84%, 72% and 71% among 0–14-year-olds 15–64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197-mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73–85) and 90% (95% CI: 85–94) without this mutation. The 2022–23 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).
- Open Access
- 21 November 2022
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13069
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study
Background: In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza.
- 21 November 2022
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13069
Open AccessInfluenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study
Background: In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza.
- Open Access
- 21 October 2022
- Published by Wiley
Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study
Background: In 2021–22, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11,000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95%CI: 43–89) and 81% (95%CI: 44–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95%CI: 12–42) and 25% (95%CI: -41–61), 33% (95%CI: 14–49) and 26% (95% CI: -22 to 55) among those aged 0–14, 15–64 and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95%CI: -6–39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but 8 belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–22 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.
- 21 October 2022
- Published by Wiley
Open AccessInfluenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study
Background: In 2021–22, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11,000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95%CI: 43–89) and 81% (95%CI: 44–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95%CI: 12–42) and 25% (95%CI: -41–61), 33% (95%CI: 14–49) and 26% (95% CI: -22 to 55) among those aged 0–14, 15–64 and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95%CI: -6–39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but 8 belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–22 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.